Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04291859 · ClinicalTrials.gov registry record · Phase 1
Lu AF28996 in Participants With Parkinson's Disease (PD)
A Phase 1 study of Parkinson Disease, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 15
- Study locations
NCT04291859: Completed Phase 1 study of Parkinson Disease, sponsored by H. Lundbeck A/S.
NCT04291859 is a Phase 1 study of Parkinson Disease that has completed, run by H. Lundbeck A/S. The registered enrollment target is 57 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04291859, a Phase 1 study of Parkinson Disease, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Primary Outcome
Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)
Conditions Studied
Interventions
- DRUG Lu AF28996
Study Locations (15)
Other
- Curiositas-ad-sanum - Hamburg
- QPS Netherlands BV - Leeuwarden
- Hospital Vall d´Hebron - Barcelona
- Hosp. General Catalunya - Mira-Sol
- Virgen Del Roccio - Seville
Florida
- Velocity - Hallandale
- Parkinson's Disease Treatment Center of SW FL - Port Charlotte
California
- CenExel Los Alamitos - Los Alamitos
District of Columbia
- Georgetown University - Washington D.C.
Georgia
- Atlanta Center for Medical Research - Atlanta
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Michigan
- QUEST Research Institute - Farmington Hills
Nebraska
- Neurology Consultants of Nebraska - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2026-02-12 |
| Phase | Phase 1 |
What the finished NCT04291859 record still lists
NCT04291859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Lu AF28996 is the first listed.
NCT04291859 lists 15 locations in 10 states (Other, Florida, California).
Frequently Asked Questions
What is clinical trial NCT04291859 about?
NCT04291859 is a clinical study titled "Lu AF28996 in Participants With Parkinson's Disease (PD)". The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
What is the current status of trial NCT04291859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2020-02-26. Estimated completion is 2026-02-12.
What conditions does trial NCT04291859 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04291859?
The interventions under investigation include: Lu AF28996 (DRUG).
Who is sponsoring clinical trial NCT04291859?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04291859 being conducted?
This trial has 15 study locations across California, District of Columbia, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04291859's enrollment target sits among peer trials
57 147th of 297 higher than 151 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI